Human papillomavirus (HPV) Associated Cancer Pipeline Analysis Demonstrates Novel 50+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight, 2023," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the Human papillomavirus (HPV) Associated Cancer pipeline drug profiles, including Human papillomavirus (HPV) Associated Cancer clinical trials and nonclinical stage products. It also covers the Human papillomavirus (HPV) Associated Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Human papillomavirus (HPV) Associated Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Human papillomavirus (HPV) Associated Cancer clinical trials studies, Human papillomavirus (HPV) Associated Cancer NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Human papillomavirus (HPV) Associated Cancer Pipeline Report

• DelveInsight's Human papillomavirus (HPV) Associated Cancer Pipeline report depicts a robust space with 75+ active players working to develop 50+ pipeline therapies for Human papillomavirus (HPV) Associated Cancer treatment.

• The leading Human papillomavirus (HPV) Associated Cancer Companies includes PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others.

• Promising Human papillomavirus (HPV) Associated Cancer Pipeline Therapies includes PDS0101, PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others.

• The Human papillomavirus (HPV) Associated Cancer companies and academics are working to assess challenges and seek opportunities that could influence in Human papillomavirus (HPV) Associated Cancer R&D. The Human papillomavirus (HPV) Associated Cancer pipeline therapies under development are focused on novel approaches to treat/improve in Human papillomavirus (HPV) Associated Cancer.

To explore more information on the latest breakthroughs in the Human papillomavirus (HPV) Associated Cancer Pipeline treatment landscape of the report, click here Human papillomavirus (HPV) Associated Cancer Pipeline Outlook @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus (HPV) Associated Cancer Overview

Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, head and neck, anal, and carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers. Among all human cancers, 15% are caused by viral infections. Human papillomavirus (HPV) accounts for approximately 600,000 cases of cancers of the cervix, oropharyngeal cancers, anal cancers, vulvovaginal and cancers, as well as a genital wart and recurrent papillomatosis of the lungs worldwide. HPV has an exclusively intra-epithelial infectious cycle and infects both the cutaneous and mucosal squamous epithelium. HPV type 16 and 18 are the most common oncogenic viruses among the HPVs that cause cancer.

Latest Developmental Activities in the Human papillomavirus (HPV) Associated Cancer Treatment Landscape

• In July 2022, NexImmune, Inc. received IND clearance for the Company's first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

• In July 2022, Voltron Therapeutics, Inc., announced that data from the previously announced Study '098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers. This is a well-validated murine model of HPV-related cancers. VTX-067, a Self-Assembling Vaccine (SAV) targeting select peptides from HPV-related cancers, was developed using Voltron's Self Assembling Vaccine Platform. Voltron has executed an exclusive worldwide license for this technology from The Massachusetts General Hospital's (MGH) Vaccine and Immunotherapy Center (VIC).

• In July 2022, Repertoire Immune Medicines announced its research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to identify the immune system's response at various stages of human papillomavirus-positive (HPV+) cancer, including initial oncogenesis and after successful treatment.

• In June 2022, Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years. The company received the grant to Advance Human Papillomavirus Cancer Treatment.

• In May 2022, Nykode Therapeutics announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients with HPV16-positive advanced cervical cancer. Interim results from 39 patients with a median follow up of 6 months show an ORR of 21%-including two patients who achieved a complete response and six who achieved a partial response-and a very high disease control rate of 64%. The trial enrolled a heavily pre-treated patient population with more than two thirds of the patients having received at least two previous systemic lines of treatment.

• In April 2022, SQZ Biotechnologies announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

• In May 2021, Rubius Therapeutics, Inc. announced the publication of preclinical data in the peer-reviewed journal Nature Communications, for its lead artificial antigen-presenting (aAPC) cell program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers.

For further information, refer to the detailed Human papillomavirus (HPV) Associated Cancer Unmet Needs, Human papillomavirus (HPV) Associated Cancer Market Drivers, and Human papillomavirus (HPV) Associated Cancer Market Barriers, click here for Human papillomavirus (HPV) Associated Cancer Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus (HPV) Associated Cancer Emerging Drugs Profile

STP909: Sirnaomics Inc
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.

RTX-321: Rubius Therapeutics
RTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.

BVAC-C: Cellid Co Ltd
BVAC-C uses HPV type 16/18's carcinogen gene, E6/E7's recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.

GX-188E: Genexine Inc
GX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.

ITI-2000: Immunomic Therapeutics Inc
ITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

Human papillomavirus (HPV) Associated Cancer Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Human papillomavirus (HPV) Associated Cancer. The companies which have their Human papillomavirus (HPV) Associated Cancer drug candidates in the most advanced stage, i.e. Phase III include Advaxis.

Request a sample and discover the recent advances in Human papillomavirus (HPV) Associated Cancer Ongoing Clinical Trial Analysis and Medications, click here for Human papillomavirus (HPV) Associated Cancer Treatment Landscape @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Human papillomavirus (HPV) Associated Cancer Pipeline Insight Report

• Coverage- Global

• Human papillomavirus (HPV) Associated Cancer Companies- PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others

• Human papillomavirus (HPV) Associated Cancer Pipeline Therapies- PDS0101, PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others.

• Human papillomavirus (HPV) Associated Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Human papillomavirus (HPV) Associated Cancer Market Drivers and Human papillomavirus (HPV) Associated Cancer Market Barriers, click here for Human papillomavirus (HPV) Associated Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Human papillomavirus (HPV) Associated Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human papillomavirus (HPV) Associated Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac: Advaxis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PRGN-2009: Precigen PII
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HB-200: Hookipa Pharma Inc
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Human papillomavirus (HPV) Associated Cancer Key Companies
24. Human papillomavirus (HPV) Associated Cancer Key Products
25. Human papillomavirus (HPV) Associated Cancer - Unmet Needs
26. Human papillomavirus (HPV) Associated Cancer - Market Drivers and Barriers
27. Human papillomavirus (HPV) Associated Cancer - Future Perspectives and Conclusion
28. Human papillomavirus (HPV) Associated Cancer Analyst Views
29. Human papillomavirus (HPV) Associated Cancer Key Companies
30. Appendix

Got Queries? Find out the related information on Human papillomavirus (HPV) Associated Cancer Mergers and acquisitions, Human papillomavirus (HPV) Associated Cancer Licensing Activities and Human papillomavirus (HPV) Associated Cancer Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us

Yash Bhardwaj

info@delveinsight.com

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.